Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective

Area of Science:

• Oncology
• Cancer Therapeutics
• Immunology

Background:

• Significant advancements in non-small cell lung cancer (NSCLC) therapies have emerged, including targeted therapies and immunotherapies.
• Despite progress, a substantial number of patients do not respond to existing treatments.

Purpose of the Study:

• To review key scientific developments in NSCLC therapies over the past decade.
• To highlight the need for personalized treatment strategies based on tumor characteristics and immune interactions.
• To emphasize the importance of identifying biomarkers for immunotherapy response.

Main Methods:

• Literature review of recent scientific developments in NSCLC targeted therapy and immunotherapy.
• Analysis of current challenges in patient response to these novel treatments.
• Discussion of future research directions in tumor characterization and biomarker discovery.

Main Results:

• Targeted therapies exploiting specific genetic mutations have shown promise.
• Immune checkpoint inhibitors harnessing the patient's immune system represent a major therapeutic advance.
• Many patients remain refractory to these treatments, indicating a need for further optimization.

Conclusions:

• Rational application of scientific knowledge in tumor characterization and mutation profiling is crucial for maximizing patient benefit.
• Understanding host-tumor immune interactions is key to expanding therapeutic options.
• Identification of reliable immunotherapy biomarkers is essential for predicting response to immune checkpoint inhibitors and represents a critical area for future research.